Jun 24, 2006 | NEWS
June 24, 2006 deCODE genetics (Nasdaq:DCGN) today announced positive results from its preliminary Phase II clinical trial (Phase IIa) of Cephalon Inc.’s (Nasdaq: CEPH) CEP-1347 in asthma. Data on patients receiving active drug in the trial were consistent with a...
Jun 20, 2006 | NEWS
June 20, 2006 A population-based study by a team of deCODE scientists and colleagues at Iceland’s National University Hospital published today provides a detailed look at the impact of a gene variant on risk of breast cancer. The variant is within a gene called BARD1...
May 17, 2006 | NEWS
May 17, 2006 deCODE genetics (Nasdaq:DCGN) today announced the initiation of patient enrollment in the pivotal Phase III trial for DG031, deCODE’s lead developmental compound for the prevention of heart attack. “This is an important study for deCODE and a small...
May 15, 2006 | NEWS
May 15, 2006 deCODE and Illumina Form Alliance to Develop and Commercialize DNA-based Diagnostics Companies to initiate work on molecular diagnostics for the risk of heart attack, type 2 diabetes and breast cancer Illumina to install large-scale genotyping system and...
May 7, 2006 | NEWS
May 7, 2006 Milestone in cancer genetics: a common genetic variant conferring significant risk of a common cancer in the general population Scientists at deCODE genetics (Nasdaq:DCGN) along with academic colleagues in Iceland, the US and Sweden today report the...
May 3, 2006 | NEWS
May 3, 2006 deCODE genetics (Nasdaq:DCGN) today announced that it has reached an agreement with the US Food and Drug Administration (FDA) on the design of its Phase III clinical trial for DG031, deCODE’s lead developmental compound for the prevention of heart attack....
